Related Experiment Video
Updated: Aug 5, 2026
09:45
Modification and Functionalization of the Guanidine Group by Tailor-made Precursors
Published on: April 27, 2017
Fully Validated, Multi-Kilogram cGMP Synthesis of MDMA
Jay B Nair1, Linda Hakes2, Berra Yazar-Klosinski3
1MAPS Public Benefit Corporation (MAPS PBC), 3141 Stevens Creek Blvd #40547, San Jose, California 95117, United States.
ACS Omega
|January 17, 2022
Summary
Researchers developed a validated Good Manufacturing Practice (cGMP) synthesis for 3,4-Methylenedioxymethamphetamine (MDMA). This scalable process ensures high purity MDMA for clinical trials and potential therapeutic applications.
Area of Science:
- Pharmaceutical Chemistry
- Drug Manufacturing
- Clinical Research
Background:
- 3,4-Methylenedioxymethamphetamine (MDMA) is gaining traction in clinical research.
- A standardized, Good Manufacturing Practice (cGMP)-compliant synthesis for MDMA has been lacking.
- This gap hinders large-scale clinical trials and potential therapeutic development.
Purpose of the Study:
- To report the first fully validated cGMP synthesis of MDMA.
- To establish a scalable and reproducible manufacturing process for clinical-grade MDMA.
- To ensure a reliable supply of high-purity MDMA for ongoing and future research.
Main Methods:
- A four-step synthesis process was developed, starting from a noncontrolled material.
- The synthesis was validated under cGMP conditions.
- High-performance liquid chromatography (HPLC) was used to assess chemical purity.
Main Results:
- The synthesis successfully produced up to 5 kg of MDMA (approximately 30,000 patient doses).
- Overall yield ranged from 41-53% over the four steps.
- Chemical purity consistently exceeded 99.9% by HPLC peak area across validation trials.
Conclusions:
- The described cGMP synthesis provides a validated method for producing high-purity MDMA.
- This advancement will support ongoing clinical trials investigating MDMA.
- Availability of cGMP MDMA is crucial for future therapeutic use, pending regulatory approval.
